SEARCH WITHIN CONTENT
VOLUME 8 , ISSUE 1 ( January-June, 2018 ) > List of Articles
Khaaviya N, Fahmitha Parveen S, Vezhavendhan N, Sivaramakrishnan M
Citation Information : N K, S FP, N V, M S. Pentoxifylline Therapy in the Management of Oral Submucous Fibrosis – A Review. 2018; 8 (1):19-21.
License: CC BY-NC 4.0
Published Online: 20-08-2020
Copyright Statement: Copyright © 2018; The Author(s).
Aim: Oral sub mucous fibrosis is a high risk pre malignant condition predominantly seen in the Indian subcontinent. The aim of the study was to review the effect of Pentoxifylline on the clinical and pathologic course of OSMF. Material and methods: A review study was done to analyse the efficacy of Pentoxifylline in the treatment of OSMF. We searched over PubMed and Google database for studies meeting our eligibility criteria (august 2006 to July 2017). A total of 270 patients who were clinically diagnosed as OSMF from a total of 6 studies with one meta-analyses, 2 randomized control trial, three clinical trials were included for this review. Results: Pentoxifylline is a methyxanthine derivative, which showed considerable improvement in mouth opening, tongue protrusion, difficulty in speech and swallowing. The total symptom score improved by 85.8% in Pentoxifylline. Dexamethasone and Pentoxifylline showed significant mouth opening and reduction in burning sensation. Conclusion: Pentoxifylline can bring about significant improvement in all clinical signs of maximal mouth opening, tongue protrusion, burning sensation thereby improving the quality of life. Conflicting to the above findings, one randomized clinical trial showed no significant advancement in burning sensation, mouth opening, tongue protrusion.
© Jaypee Brothers Medical Publishers (P) LTD.